Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：20

作者：

Ayyappan, Sabarish ^{[1
]}

Kim, Won Seog ^{[2
]}

Kim, Tae Min ^{[3
]}

Walewski, Jan ^{[4
]}

Cho, Seok-Goo ^{[5
]}

Jarque, Isidro ^{[6
]}

Iskierka-Jazdzewska, Elzbieta ^{[7
]}

Poon, Michelle ^{[8
]}

Oh, Sung Yong ^{[9
]}

Lim, Francesca Lorraine Wei Inng ^{[10
]}

Carpio, Cecilia ^{[11
]}

Tan, Tran-Der ^{[12
]}

Gutierrez, Antonio ^{[13
]}

Zhang, Huilai ^{[14
]}

Cao, Junning ^{[15
]}

Zhang, Mingzhi ^{[16
,17
]}

Tessoulin, Benoit ^{[18
,19
]}

Li, Jingjin ^{[20
]}

Ufkin, Melanie ^{[20
]}

Shariff, Saleem ^{[21
]}

Chi, Lei ^{[20
]}

Chaudhry, Aafia ^{[20
]}

Mohamed, Hesham ^{[20
]}

Ambati, Srikanth ^{[20
]}

Prince, H. Miles ^{[22
,23
]}

机构：

[1] Univ Iowa Hosp & Clin, Iowa City, IA USA

[2] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[4] Marii Sklodowskiej Curie Panstwowy Inst Badawczy, Narodowy Inst Onkol, Warsaw, Poland

[5] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[6] Hosp Univ La Fe, Valencia, Spain

[7] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

[8] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore

[9] Dong A Univ Hosp, Busan, South Korea

[10] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[11] Autonomous Univ Barcelona UAB, Univ Hosp Vall Hebron, Barcelona, Spain

[12] Koo Fdn, Sun Yat Sen Canc Ctr, Taipei, Taiwan

[13] Hosp Univ Son Espases, IdISBa Palma, Palma De Mallorca, Spain

[14] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[15] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[16] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[17] Lymphoma Diag & Treatment Ctr Henan Prov, Zhengzhou, Peoples R China

[18] Nantes Univ, Sch Med, Nantes, France

[19] Univ Hosp Nantes, Nantes, France

[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[21] Regeneron UK Ltd, Uxbridge, England

[22] Epworth Healthcare, Melbourne, Australia

[23] Univ Melbourne, Melbourne, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179818

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[21] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Vukcevic, Mirko
Yung, Mallory
Khan, Mali
Houpt, Bethany
Schnell, Frederick
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377
[22] The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)
Lenz, Georg
Rutherford, Sarah C.
Davies, Andrew
Zinzani, Pier Luigi
Salles, Gilles
Hasskarl, Jens
Margunato-Debay, Sandra
Rodrigues, Filipe
Nientker, Lisette
Balradj, Janita
Alleman, Cathelijne
BLOOD, 2018, 132
[23] Patient, caregiver, and physician preferences for treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Vukcevic, Mirko
Yung, Mallory
Khan, Maliha
Schnell, Frederick Mark
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18710 - E18710
[24] Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective
Moertl, Bernhard
Dreyling, Martin
Schmidtl, Christian
Hoster, Eva
Schoel, Wolfgang
V. Bergwelt-Baildon, Michael
Berger, Karin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 474 - 482
[25] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
Longcor, J.
Oliver, K.
Friend, J.
Callandar, N.
ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
[26] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
Peters, Anthea
Nowakowski, Grzegorz S.
Dabas, Rosy
Amoloja, Theresa
Xue, Zhenyi
Koch, Caroline
Waltl, Eva E.
Fleury, Isabelle
BLOOD, 2022, 140 : 3811 - 3813
[27] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Maria Jose
Schuster, Stephen J.
Salles, Gilles
Maziarz, Richard T.
Anak, Ozlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
CANCER RESEARCH, 2018, 78 (13)
[28] Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion
Hutchings, M.
Dickinson, M.
Carlo-Stella, C.
Morschhauser, F.
Bachy, E.
Corradini, P.
Iacoboni, G.
Khan, C.
Wrobel, T.
Offner, F.
Trneny, M.
Wu, S. -J.
Cartron, G.
Hertzberg, M.
Sureda, A.
Perez-Callejo, D.
Lundberg, L.
Relf, J.
Clark, E.
Humphrey, K.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 50 - 51
[29] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Chen, Robert W.
Ansel, Stephen Maxted
Zinzani, Pier Luigi
Vacirca, Jeffrey L.
Lopez-Guillermo, Armando
Hutchings, Martin
Jurczak, Wojciech
Hess, Georg
Le Gouill, Steven
Offner, Fritz
Santoro, Armando
Salles, Gilles A.
Stypinski, Darla
Laird, Douglas
Pavlov, Dmitri
Andreola, Giovanna
Fly, Kolette D.
Woolfson, Adrian
Collins, Graham P.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[30] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Goy, Andre
Ramchandren, Radhakrishnan
Ghosh, Nilanjan
Munoz, Javier
Morgan, David S.
Dang, Nam H.
Knapp, Mark
Delioukina, Maria
Kingsley, Edwin C.
Anh Tran
Ping, Jerry
Beaupre, Darrin M.
Neuenburg, Jutta K.
Ruan, Jia
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →